In Brief: Neuropsychiatric Events with Montelukast

Date: May 4, 2020 Issue #:  1597Summary:  The FDA is requiring stronger warnings in the labeling of the leukotriene receptor antagonist montelukast (Singulair, and generics) about the risk of suicidal behavior and other serious neuropsychiatric events associated with its use.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Accolate Allergic rhinitis Allergies Antihistamines Asthma corticosteroids Drug Safety Montelukast Singulair Zafirlukast Zileuton Zyflo Source Type: research